DOCSLIB.ORG

PAREXEL Bioanalytical Division Offers a Wide Range of Bioanalytical Services

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
PAREXEL Bioanalytical Division Offers a Wide Range of Bioanalytical Services PAREXEL Bioanalytical Laboratory Services Page 2 PAREXEL Bioanalytical Division offers a wide range of bioanalytical services. PK analysis Clinical laboratory -16 LC-MS/MS instruments – Routine safety testing (serology, Applied Bioscience API2000 haematology and clinical chemistry) to API5500 Immunochemistry laboratory -Development and validation PK/PD analysis of macromolecules of new bioanalytical assays using RIA, ELISA, ECL -More than 500 validated methods Cellular assays are performed used in over 2,500 clinical & using Flow Cytometry and preclinical trials to date Cytometric Bead Array (CBA) Preferred partnerships with accredited laboratories are in place, for specialized biomarker assays not directly provided by PAREXEL Several methods have been developed for proprietary drugs and these are not listed in this document due to confidentiality Our validation procedures and SOP’s are in compliance with the United States of America (FDA)1 and European (EMEA)2 guidelines The laboratories are GLP & ISO17025 certified and were successfully inspected by the FDA, MHRA, WHO and EMA 1 Guidance for Industry, Bioanalytical Method Validation (2001) and Workshop/Conference Report – Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays (Viswanathan et al., AAPS J. 2007; 9 (1) Article 4). 2 ”CPMP/EWP/QWP/1401/98, Note for Guidance on the Investigation of Bioavailability and Bioequivalence" (EMEA) Bold = Compounds that have active metabolites to be considered for analysis Blue Band = Active metabolite of the molecule referenced above in bold 2 PAREXEL Bioanalytical Laboratory Services Page 3 PAREXEL Bioanalytical Laboratory Services Page 2 Validated assay methods Storage Light Drug LLOQ Technique Matrix Temp Sensitivity Acamprosate 1.08 ng/ml LC-MS/MS Human Plasma -20 °C Normal Light Acarbose 0.32 ng/ml LC-MS/MS Human Plasma -20 °C Normal Light Acebutolol 5.56 ng/ml HPLC Fluorescence Human Plasma -20 °C Normal Light Diacetolol 20.9 ng/ml HPLC Fluorescence Human Plasma -20 °C Normal Light PAREXEL Bioanalytical Division offers Aceclofenac 25.1 ng/ml LC-MS/MS Human Plasma -20 °C Normal Light a wide range of bioanalytical services. Acetaminophen 0.16 µg/ml LC-MS/MS Human Plasma -20 °C Normal Light Acetazolamide 14.2 ng.ml LC-MS/MS Human Plasma -70 °C Normal Light Acetylsalicylic Acid 28.1 ng/ml HPLC Fluorescence Human Plasma -70 °C Normal Light PK analysis Clinical laboratory Salicylic Acid 40.0 ng/ml HPLC Fluorescence Human Plasma -70 °C Normal Light -16 LC-MS/MS instruments – Routine safety testing (serology, Applied Bioscience API2000 haematology and clinical chemistry) Acyclovir 5.03 ng/ml LC-MS/MS Human Plasma -20 °C Normal Light to API5500 α-GST 2.50 ng/ml ELISA Urine -20 °C Normal Light Immunochemistry laboratory -Development and validation PK/PD analysis of macromolecules α-GST 0.74 ng/ml ELISA Human Serum -20 °C Normal Light of new bioanalytical assays using RIA, ELISA, ECL Alfuzosin 0.34 ng/ml LC-MS/MS Human Plasma -20 °C Normal Light -More than 500 validated methods Cellular assays are performed Alendronate 1.95 ng/ml HPLC Fluorescence Urine -20 °C Normal Light used in over 2,500 clinical & using Flow Cytometry and Allopurinol 0.35 µg/ml HPLC UV Human Plasma -20 °C Normal Light preclinical trials to date Cytometric Bead Array (CBA) Oxypurinol 0.64 µg/ml HPLC UV Human Plasma -20 °C Normal Light Preferred partnerships with accredited laboratories are in place, for specialized biomarker assays not directly provided by PAREXEL Alprazolam 0.50 ng/ml GC ECD Human Plasma -20 °C Normal Light Several methods have been developed for proprietary drugs and these are not listed in this document due to confidentiality Altizide 3.03 ng/ml HPLC UV Human Plasma -20 °C Normal Light Our validation procedures and SOP’s are in compliance with the United States of America (FDA)1 and European (EMEA)2 guidelines The laboratories are GLP & ISO17025 certified and were successfully inspected by the FDA, MHRA, WHO and EMA Ambroxol 0.28 ng/ml LC-MS/MS Human Plasma -20 °C Normal Light 1 Guidance for Industry, Bioanalytical Method Validation (2001) and Workshop/Conference Report – Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays (Viswanathan et al., AAPS J. 2007; 9 (1) Article 4). Amiloride 0.28 ng/ml HPLC UV Human Plasma -20 °C Normal Light 2 ”CPMP/EWP/QWP/1401/98, Note for Guidance on the Investigation of Bioavailability and Bioequivalence" (EMEA) Amiodarone 1.57 ng/ml HPLC UV Human Plasma -20 °C Normal Light Bold = Compounds that have active metabolites to be considered for analysis Blue Band = Active metabolite of the molecule referenced above in bold Bold = Compounds that have active metabolites to be considered for analysis Blue Band = Active metabolite of the molecule referenced above in bold 3 PAREXEL Bioanalytical Laboratory Services Page 4 Validated assay methods Storage Light Drug LLOQ Technique Matrix Temp Sensitivity N-desethylamiodarone 6.96 ng/ml HPLC UV Human Plasma -20 °C Normal Light Amisulpride 2.40 ng/ml HPLC UV Human Plasma -20 °C Normal Light Amitriptyline 0.89 ng/ml GC NPD Human Plasma -20 °C Normal Light Amlodipine 0.05 ng/ml LC-MS/MS Human Plasma -20 °C Light Sensitive Amoxycillin 98.7 ng/ml HPLC UV Human Plasma -70 °C Normal Light Anagrelide 0.09 ng/ml LC-MS/MS Human Plasma -20 °C Normal Light Antipyrine 0.60 µg/ml HPLC UV Urine -70 °C Normal Light 4-OH-antipyrine 1.94 µg/ml HPLC UV Urine -70 °C Normal Light Nor-Antipyrine 1.05 µg/ml HPLC UV Urine -70 °C Normal Light Anti-Insulin Antibodies 200 ng/ml RIPA Human Plasma -20 °C Normal Light (semi-quantitative) (sensitivity) Atenolol 13.0 ng/ml HPLC Fluorescence Human Plasma -70 °C Normal Light Atovaquone 0.44 µg/ml HPLC UV Human Plasma -20 °C Normal Light Atropine 0.61 µg/ml LC-MS/MS Colic Mixture -20 °C Normal Light Azathioprine 0.47 ng/ml LC-MS/MS Human Plasma -70 °C Light Sensitive 6-Mercaptopurine 0.47 ng/ml LC-MS/MS Human Plasma -70 °C Light Sensitive Baclofen 35.0 ng/ml HPLC UV Human Plasma -20 °C Normal Light Benfluorex 0.39 ng/ml LC-MS/MS Human Plasma -70 °C Normal Light Norfenfluramine 0.20 ng/ml LC-MS/MS Human Plasma -70 °C Normal Light THEP 0.39 ng/ml LC-MS/MS Human Plasma -70 °C Normal Light Betamethazone 58.7 pg/ml LC-MS/MS Human Plasma -20 ºC Normal Light Bezafibrate 0.10 µg/ml HPLC UV Human Plasma -20 °C Normal Light Bold = Compounds that have active metabolites to be considered for analysis Blue Band = Active metabolite of the molecule referenced above in bold 4 PAREXEL Bioanalytical Laboratory Services Page 4 PAREXEL Bioanalytical Laboratory Services Page 5 Validated assay methods Validated assay methods Storage Light Storage Light Drug LLOQ Technique Matrix Drug LLOQ Technique Matrix Temp Sensitivity Temp Sensitivity N-desethylamiodarone 6.96 ng/ml HPLC UV Human Plasma -20 °C Normal Light Bicalutamide 30.3 ng/ml LC-MS/MS Human Plasma -70 °C Normal Light Amisulpride 2.40 ng/ml HPLC UV Human Plasma -20 °C Normal Light Bindarit 0.10 µg/ml LC-MS/MS Plasma/Urine -20 °C Normal light Amitriptyline 0.89 ng/ml GC NPD Human Plasma -20 °C Normal Light Bisoprolol 0.88 ng/ml HPLC Fluorescence Human Plasma -20 °C Normal Light Amlodipine 0.05 ng/ml LC-MS/MS Human Plasma -20 °C Light Sensitive Bromazepam 1.56 ng/ml GC ECD Human Plasma -20 °C Normal Light Amoxycillin 98.7 ng/ml HPLC UV Human Plasma -70 °C Normal Light Budesonide 20.8 pg/ml LC-MS/MS Human Plasma -70 °C Light sensitive Anagrelide 0.09 ng/ml LC-MS/MS Human Plasma -20 °C Normal Light Buflomedil 0.15 µg/ml HPLC UV Human Plasma -20 °C Normal Light Antipyrine 0.60 µg/ml HPLC UV Urine -70 °C Normal Light Bumetanide 0.39 ng/ml HPLC UV Human Plasma -20 °C Normal Light 4-OH-antipyrine 1.94 µg/ml HPLC UV Urine -70 °C Normal Light Bupropion 7.81 ng/ml LC-MS/MS Human Plasma -20 °C Normal Light Nor-Antipyrine 1.05 µg/ml HPLC UV Urine -70 °C Normal Light Hydroxybupropion 7.65 ng/ml LC-MS/MS Human Plasma -20 °C Normal Light Anti-Insulin Antibodies 200 ng/ml Cabergoline 1.50 pg/ml LC-MS/MS Human Plasma -20 °C Normal Light RIPA Human Plasma -20 °C Normal Light (semi-quantitative) (sensitivity) Caffeine 26.6 ng/ml LC-MS/MS Human Plasma -20 °C Normal Light Atenolol 13.0 ng/ml HPLC Fluorescence Human Plasma -70 °C Normal Light Paraxanthine 26.2 ng/ml LC-MS/MS Human Plasma -20 °C Normal Light Atovaquone 0.44 µg/ml HPLC UV Human Plasma -20 °C Normal Light Calanolide 22.3 ng/ml HPLC Fluorescence Human Plasma -20 °C Light Sensitive Atropine 0.61 µg/ml LC-MS/MS Colic Mixture -20 °C Normal Light Candesartan 2.49 ng/ml LC-MS/MS Human Plasma -20 °C Light Sensitive Azathioprine 0.47 ng/ml LC-MS/MS Human Plasma -70 °C Light Sensitive Capecitabine 7.81 ng/ml LC-MS/MS Human Plasma -70 °C Normal Light 6-Mercaptopurine 0.47 ng/ml LC-MS/MS Human Plasma -70 °C Light Sensitive Captopril 23.3 ng/ml HPLC UV Human Plasma -20 °C Normal Light Baclofen 35.0 ng/ml HPLC UV Human Plasma -20 °C Normal Light Carbamazepine 2.64 ng/ml LC-MS/MS Human Plasma -20 °C Normal Light Benfluorex 0.39 ng/ml LC-MS/MS Human Plasma -70 °C Normal Light Carbamazepine-10,11-epoxide 5.15 ng/ml LC-MS/MS Human Plasma -20 °C Normal Light Norfenfluramine 0.20 ng/ml LC-MS/MS Human Plasma -70 °C Normal Light Carbamazepine -10,11-diol 9.12 ng/ml HPLC UV Human Plasma -20 °C Normal Light THEP 0.39 ng/ml LC-MS/MS Human Plasma -70 °C Normal Light Carbidopa 2.30 ng/ml LC-MS/MS Human Plasma -70 °C Normal Light Betamethazone 58.7 pg/ml LC-MS/MS Human Plasma -20 ºC Normal Light Carvedilol 1.26 ng/ml LC-MS/MS Human Plasma -20 °C
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0152273 A1 Merchant Et Al
    US 20170152273A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0152273 A1 Merchant et al. (43) Pub. Date: Jun. 1, 2017 (54) TOPCAL PHARMACEUTICAL Publication Classification FORMULATIONS FOR TREATING (51) Int. Cl. NFLAMMLATORY-RELATED CONDITIONS C07F 5/02 (2006.01) Applicant: A6II 47/06 (2006.01) (71) Anacor Pharmaceuticals Inc., New A69/06 (2006.01) York, NY (US) A6IR 9/00 (2006.01) (72) Inventors: Tejal Merchant, Cupertino, CA (US); A6II 47/8 (2006.01) Dina Jean Coronado, Danville, CA A6II 45/06 (2006.01) (US); Charles Edward Lee, Union A6II 47/10 (2006.01) City, CA (US); Delphine Caroline A6II 3/69 (2006.01) Imbert, Cupertino, CA (US); Sylvia (52) U.S. Cl. Zarela Yep, Milpitas, CA (US) CPC .............. C07F 5/025 (2013.01); A61K 47/10 (2013.01); A61K 47/06 (2013.01); A61K3I/69 (73) Assignee: Anacor Pharmaceuticals Inc., New (2013.01); A61K 9/0014 (2013.01); A61 K York, NY (US) 47/183 (2013.01); A61K 45/06 (2013.01); A61K 9/06 (2013.01); C07B 2.200/13 (21) Appl. No.: 15/364,347 (2013.01) (22) Filed: Nov. 30, 2016 (57) ABSTRACT Related U.S. Application Data (60) Provisional application No. 62/420,987, filed on Nov. Topical pharmaceutical formulations, and methods of treat 11, 2016, provisional application No. 62/260,716. ing inflammatory conditions with these formulations, are filed on Nov. 30, 2015. disclosed. Patent Application Publication Jun. 1, 2017. Sheet 1 of 4 US 2017/0152273 A1 ?zzzzzzzzzzzzzzzzzzzzzzzzzzzz ????????????????????????????????????????????????????????????????????? S&S&S Šx&N Sssssssssssssssssssssssssssssssssssssss (r) eqn. O. peppy jeeNA go eunO/A Patent Application Publication Jun.
    [Show full text]
  • Supplementary Information
    Supplementary Information Network-based Drug Repurposing for Novel Coronavirus 2019-nCoV Yadi Zhou1,#, Yuan Hou1,#, Jiayu Shen1, Yin Huang1, William Martin1, Feixiong Cheng1-3,* 1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA 2Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA 3Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA #Equal contribution *Correspondence to: Feixiong Cheng, PhD Lerner Research Institute Cleveland Clinic Tel: +1-216-444-7654; Fax: +1-216-636-0009 Email: [email protected] Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. Supplementary Table S2. Protein sequence identities across 5 protein regions in 15 coronaviruses. Supplementary Table S3. HCoV-associated host proteins with references. Supplementary Table S4. Repurposable drugs predicted by network-based approaches. Supplementary Table S5. Network proximity results for 2,938 drugs against pan-human coronavirus (CoV) and individual CoVs. Supplementary Table S6. Network-predicted drug combinations for all the drug pairs from the top 16 high-confidence repurposable drugs. 1 Supplementary Table S1. Genome information of 15 coronaviruses used for phylogenetic analyses. GenBank ID Coronavirus Identity % Host Location discovered MN908947 2019-nCoV[Wuhan-Hu-1] 100 Human China MN938384 2019-nCoV[HKU-SZ-002a] 99.99 Human China MN975262
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • W W W .Bio Visio N .Co M New Products Added in 2020
    New products added in 2020 Please find below a list of all the products added to our portfolio in the year 2020. Assay Kits Product Name Cat. No. Size Product Name Cat. No. Size N-Acetylcysteine Assay Kit (F) K2044 100 assays Human GAPDH Activity Assay Kit II K2047 100 assays Adeno-Associated Virus qPCR Quantification Kit K1473 100 Rxns Human GAPDH Inhibitor Screening Kit (C) K2043 100 assays 20 Preps, Adenovirus Purification Kit K1459 Hydroxyurea Colorimetric Assay Kit K2046 100 assays 100 Preps Iodide Colorimetric Assay Kit K2037 100 assays Aldehyde Dehydrogenase 2 Inhibitor Screening Kit (F) K2011 100 assays Laccase Activity Assay Kit (C) K2038 100 assays Aldehyde Dehydrogenase 3A1 Inhibitor Screening Kit (F) K2060 100 assays 20 Preps, Lentivirus and Retrovirus Purification Kit K1458 Alkaline Phosphatase Staining Kit K2035 50 assays 100 Preps Alpha-Mannosidase Activity Assay Kit (F) K2041 100 assays Instant Lentivirus Detection Card K1470 10 tests, 20 tests Beta-Mannosidase Activity Assay Kit (F) K2045 100 assays Lentivirus qPCR Quantification Kit K1471 100 Rxns 50 Preps, Buccal Swab DNA Purification Kit K1466 Maleimide Activated KLH-Peptide Conjugation Kit K2039 5 columns 250 Preps Methionine Adenosyltransferase Activity Assay Kit (C) K2033 100 assays CD38 Activity Assay Kit (F) K2042 100 assays miRNA Extraction Kit K1456 50 Preps EZCell™ CFDA SE Cell Tracer Kit K2057 200 assays MMP-13 Inhibitor Screening Kit (F) K2067 100 assays Choline Oxidase Activity Assay Kit (F) K2052 100 assays Mycoplasma PCR Detection Kit K1476 100 Rxns Coronavirus
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Review Article Role of Antidiarrhoeal Drugs As Adjunctive Therapies for Acute Diarrhoea in Children
    Hindawi Publishing Corporation International Journal of Pediatrics Volume 2013, Article ID 612403, 14 pages http://dx.doi.org/10.1155/2013/612403 Review Article Role of Antidiarrhoeal Drugs as Adjunctive Therapies for Acute Diarrhoea in Children Christophe Faure Division of Gastroenterology, Department of Pediatrics, CHU Sainte-Justine, Montreal, QC, Canada H3T 1C5 Correspondence should be addressed to Christophe Faure; [email protected] Received 25 October 2012; Revised 2 January 2013; Accepted 2 January 2013 Academic Editor: Catherine Bollard Copyright © 2013 Christophe Faure. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Acute diarrhoea is a leading cause of child mortality in developing countries. Principal pathogens include Escherichia coli, rotaviruses, and noroviruses. 90% of diarrhoeal deaths are attributable to inadequate sanitation. Acute diarrhoea is the second leading cause of overall childhood mortality and accounts for 18% of deaths among children under five. In 2004 an estimated 1.5 million children died from diarrhoea, with 80% of deaths occurring before the age of two. Treatment goals are to prevent dehydration and nutritional damage and to reduce duration and severity of diarrhoeal episodes. The recommended therapeutic regimen is to provide oral rehydration solutions (ORS) and to continue feeding. Although ORS effectively mitigates dehydration, it has no effect on the duration, severity, or frequency of diarrhoeal episodes. Adjuvant therapy with micronutrients, probiotics, or antidiarrhoeal agents may thus be useful. The WHO recommends the use of zinc tablets in association with ORS.The ESPGHAN/ESPID treatment guidelines consider the use of racecadotril, diosmectite, or probiotics as possible adjunctive therapy to ORS.
    [Show full text]
  • Review Article Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Hindawi Publishing Corporation Dermatology Research and Practice Volume 2012, Article ID 923134, 6 pages doi:10.1155/2012/923134 Review Article Barrier-Restoring Therapies in Atopic Dermatitis: Current Approaches and Future Perspectives Y. Valdman-Grinshpoun,1, 2 D. Ben-Amitai,1, 3 and A. Zvulunov1, 4 1 Pediatric Dermatology Unit, Schneider Children’s Medical Center of Israel, 49202 Petach Tikva, Israel 2 Department of Dermatology, Szold Health Center, Clalit Health Services, 84894 Beer-Sheva, Israel 3 Sackler Faculty of Medicine, Tel Aviv University, 69978 Tel Aviv, Israel 4 Medical School for International Health, Faculty of Medicine, Ben-Gurion University of the Negev, 84105 Beer-Sheva, Israel Correspondence should be addressed to Y. Valdman-Grinshpoun, [email protected] Received 21 April 2012; Accepted 18 June 2012 Academic Editor: Georgios Stamatas Copyright © 2012 Y. Valdman-Grinshpoun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Atopic dermatitis is a multifactorial, chronic relapsing, inflammatory disease, characterized by xerosis, eczematous lesions, and pruritus. The latter usually leads to an “itch-scratch” cycle that may compromise the epidermal barrier. Skin barrier abnormalities in atopic dermatitis may result from mutations in the gene encoding for filaggrin, which plays an important role in the formation of cornified cytosol. Barrier abnormalities render the skin more permeable to irritants, allergens, and microorganisms. Treatment of atopic dermatitis must be directed to control the itching, suppress the inflammation, and restore the skin barrier.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • A 0.70% E 0.80% Is 0.90%
    US 20080317666A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317666 A1 Fattal et al. (43) Pub. Date: Dec. 25, 2008 (54) COLONIC DELIVERY OF ACTIVE AGENTS Publication Classification (51) Int. Cl. (76) Inventors: Elias Fattal, Paris (FR); Antoine A6IR 9/00 (2006.01) Andremont, Malakoff (FR); A61R 49/00 (2006.01) Patrick Couvreur, A6II 5L/12 (2006.01) Villebon-sur-Yvette (FR); Sandrine A6IPI/00 (2006.01) Bourgeois, Lyon (FR) (52) U.S. Cl. .......................... 424/1.11; 424/423; 424/9.1 (57) ABSTRACT Correspondence Address: Drug delivery devices that are orally administered, and that David S. Bradlin release active ingredients in the colon, are disclosed. In one Womble Carlyle Sandridge & Rice embodiment, the active ingredients are those that inactivate P.O.BOX 7037 antibiotics, such as macrollides, quinolones and beta-lactam Atlanta, GA 30359-0037 (US) containing antibiotics. One example of a Suitable active agent is an enzyme Such as beta-lactamases. In another embodi ment, the active agents are those that specifically treat colonic (21) Appl. No.: 11/628,832 disorders, such as Chrohn's Disease, irritable bowel syn drome, ulcerative colitis, colorectal cancer or constipation. (22) PCT Filed: Feb. 9, 2006 The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethylene imine. The high crosslink density of the polyethyleneimine is (86). PCT No.: PCT/GBO6/OO448 believed to stabilize the pectin beads for a sufficient amount of time such that a Substantial amount of the active ingredi S371 (c)(1), ents can be administered directly to the colon.
    [Show full text]
  • Racecadotril in the Treatment of Acute Diarrhea in Children
    Eberlin et al. BMC Pediatrics (2018) 18:124 https://doi.org/10.1186/s12887-018-1095-x RESEARCH ARTICLE Open Access Racecadotril in the treatment of acute diarrhea in children: a systematic, comprehensive review and meta-analysis of randomized controlled trials Marion Eberlin1, Min Chen2, Tobias Mueck1 and Jan Däbritz3,4* Abstract Background: Racecadotril is a guideline-recommended option for the treatment of acute diarrhea in children but existing guidelines and previous reviews of the field are based on a small fraction of published evidence. Therefore, we have performed a systematic search for randomized controlled trials evaluating racecadotril as add-on or in comparison to other treatments. Methods: A search was performed in PubMed, Scopus and Google Scholar without limits about country of origin or reporting language. A meta-analysis was conducted for the five most frequently used efficacy parameters. Results: We have retrieved 58 trials, from nine countries including six in comparison to placebo, 15 in comparison to various active treatments and 41 as add-on to various standard treatments (some multi-armed studies allowing more than one comparison). Trials used 45 distinct efficacy parameters, most often time to cure, % of cured children after 3 days of treatment, global efficacy and number of stools on second day of treatment. Racecadotril was superior to comparator treatments in outpatients and hospitalized patients with a high degree of consistency as confirmed by meta-analysis for the five most frequently used outcome parameters. For instance, it reduced time to cure from 106.2 h to 78.2 h (mean reduction 28.0 h; P < 0.0001 in 24 studies reporting on this parameter).
    [Show full text]